We are live on
!
Find out more
FIS
FCPM III Services Portfolio holdings
AUM
$722M
1-Year Est. Return
73.61%
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
+73.61%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$339M
AUM Growth
–
Cap. Flow
+$307M
Cap. Flow
% of AUM
90.31%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
6
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NewAmsterdam Pharma
NAMS
|
+$108M |
| 2 |
enGene Therapeutics
ENGN
|
+$76.8M |
| 3 |
Dyne Therapeutics
DYN
|
+$59.9M |
| 4 |
Replimune Group
REPL
|
+$56.4M |
| 5 |
enGene Therapeutics Warrants
ENGNW
|
+$2.98M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.28% |
Similar funds
ZDA
ZAM
AF
UW
PPW
VCM
FFM
WLIM
FCPM III Services's Q4 2023 Portfolio in Review
Q4 2023 is the first quarter with a 13F filing on record for FCPM III Services, which disclosed 6 positions worth $339M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is NewAmsterdam Pharma: 11,831,461 shares worth $132M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets.
- FCPM III Services's largest Q4 2023 buy was NewAmsterdam Pharma: 11,831,461 shares worth $132M.
- FCPM III Services's ten largest holdings make up 100% of its $339M portfolio in Q4 2023.
- FCPM III Services disclosed 6 positions in Q4 2023, its first 13F filing on record.
Based on FCPM III Services's 13F filing for Q4 2023, filed 7 Mar 2024.